Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
To explore the safety and efficacy of Albumin-Bound Paclitaxel/Platinum based concurrent chemoradiotherapy Followed by PD-1 inhibitor (Sintilimab) in locally advanced cervical cancer
Locally Advanced Cervical Carcinoma|Concurrent Chemoradiotherapy|Immunotherapy
DRUG: Albumin-Bound Paclitaxel, cisplatin, Sintilimab
progression disease free survival, the time interval from the date of treatment to disease progression, local or distant recurrence., -2 years|safety of Albumin-Bound Paclitaxel/cisplatin based concurrent chemoradiotherapy followed by Sintilimab, the occurrence and grade of side effect from treatment according to the CTCAE 4.0 and NCCN clinical practice guidelines in the evaluation treatment-related toxicity (through the symptoms, physical examination, and also through blood/image/encoscopy examination, such as blood routine, liver and renal function, TSH/T3/T4/ACTH concentration, myocardial enzymes, and EKG, echocardiography, CT, et al)., -1 years
Objective Response Rate (ORR), the percentage of the participants in the population who have a Complete Response or Partial Response accordingly to RECIST 1.1, 3 months|distant-metastasis free survival, the time interval from the date of treatment to distant recurrence., -2 years
Patients with pathologically confirmed locally advanced cervical cancer will be treated with concurrent chemoradiotherapy (weekly Albumin-Bound Paclitaxel and cisplatin), followed by Sintilimab 200mg q3w for 8 cycles.